




河南省人民医院
参考文献:
1.
2.Oldham JM, et al. Nerandomilast in idiopathic pulmonary fibrosis: data from the whole follow-up period of the FIBRONEER-IPF trial. Am J Respir Crit Care Med. 2026 Feb 21aamag058.
3.Behr J, et al. Pharmacological Treatment of Idiopathic Pulmonary Fibrosis (Update) and Progressive Pulmonary Fibroses: S2k Guideline of the German Respiratory Society. Respiration. 2024;103(12):782-810.
4.Kato M, et al. Clinical Significance of Continuable Treatment with Nintedanib Over 12 Months for Idiopathic Pulmonary Fibrosis in a Real-World Setting. Drug Des Devel Ther. 2021 Jan 18;15:223-230.
5.Takehara K, et al. Differential Discontinuation Profiles between Pirfenidone and Nintedanib in Patients with Idiopathic Pulmonary Fibrosis. Cells. 2022 Jan 2;11(1):143.
6.Gregor J, et al. The Impact of Switching to a Second Antifibrotic in Patients With Idiopathic Pulmonary Fibrosis: A Retrospective Multicentre Study From the EMPIRE Registry. Arch Bronconeumol. 2024 Feb;60(2):80-87.
7.https://www.boehringer-ingelheim.cn/renleijiankang/feibujibing/feixianweihua/nerandomilastipf
8.https://www.nmpa.gov.cn/zhuanti/cxylqx/cxypxx/20251028100022132.html
9.Richeldi L, et al. Nerandomilast in Patients with Idiopathic Pulmonary Fibrosis. N Engl J Med. 2025 Jun 12;392(22):2193-2202.
审批号:SC-CN-19068
